Law360, New York (April 26, 2004, 12:00 AM ET) -- In a blow to U.K. drug maker GlaxoSmithKline, the U.S. Court of Appeals for the Federal Circuit has rejected a key claim for the U.S. patent covering Paxil (paroxetine hydrochloride), the world’s top-selling antidepressant.
Glaxo had sued Canadian generic maker Apotex, the first company to challenge the validity of patents covering Paxil and the first to gain approval from the U.S. Food and Drug Administration for a generic version of the drug.
Paxil is the leading antidepressant drug on the market with annual worldwide sales totaling...
Federal Circuit Rules For Apotex In Paxil Patent Suit
To view the full article, take a free trial now.
